<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554671</url>
  </required_header>
  <id_info>
    <org_study_id>IAB 06-269</org_study_id>
    <nct_id>NCT00554671</nct_id>
  </id_info>
  <brief_title>Pharmacist-led Group Medical Visits to Help With Diabetes Management</brief_title>
  <acronym>MEDIC-1 year</acronym>
  <official_title>Group Intervention for DM Guideline Implementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site open label randomized controlled study of patients with type 2 diabetes
      undergoing pharmacist-led group medical visits that include education by a multi-disciplinary
      personnel, behavioral modification and pharmacotherapy case management vs. usual care
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Background: Diabetes, hypertension, and dyslipidemia are chronic diseases that can
      lead to heart attack and stroke, and require interventions at patient and organizational
      levels to promote sustainable lifestyle and medication changes for cardiac risk reduction
      that are costly. Group intervention has emerged as a potentially cost-saving patient-centered
      approach to help achieve the necessary lifestyle and medication changes for the treatment of
      some chronic diseases, but its efficacy in absence of direct physician participation is not
      well demonstrated in diabetes. Our preliminary data have shown that our pharmacist-based,
      group diabetes management program at the Providence VAMC has achieved significant
      improvements in glycemic control and variable success toward improvement in blood pressure
      and lipid control in type 2 diabetic patients, through education, behavioral intervention and
      aggressive pharmacotherapy in 4 weekly group sessions. However, we do not know the long-term
      sustainability of this intervention, the exportability, the costs to the VA and the
      health-related quality-of-life implications of patients enrolled in our programs.

      Project Objectives: To assess whether a non-physician-based, group diabetes behavioral and
      pharmacotherapy intervention program for 12 months will: 1. improve cardiac risk factors, 2.
      improve health-related quality-of-life, 3. add only minimal institutional cost; when compared
      to usual care in veterans with type 2 diabetes.

      Project Methods: We propose a 3-site randomized-controlled study to test the efficacy of a
      pharmacist-based, group diabetes behavioral and pharmacotherapy intervention program
      (treatment arm) for 13 months vs. usual care (control arm) in achieving cardiac risk
      reduction in type 2 diabetic patients with Hemoglobin A1c &gt;7% and at least one other cardiac
      risk factor such as smoking, hyperlipidemia or hypertension not at national guideline
      recommended goals. The interventions in the treatment arm will consist of two phases. Phase 1
      (intensive intervention) consists of weekly group sessions of education by a nurse, a
      physical therapist, and a dietician; and behavioral modification and medication titration by
      a clinical pharmacist targeting the control of glycemia, smoking, blood pressure, and lipids
      for 4 weeks. Phase 2 consists of quarterly booster sessions for 1 year to prevent relapse.
      Patients in the control arm will continue on usual care. Our study endpoints will be the
      difference between the 2 groups after 13 months of study enrollment in: 1) hemoglobin a1c,
      blood pressure, LDL cholesterol and smoking 2) health-related quality of life (SF-36V)
      scores, and 3) healthcare costs from the VA perspective. A total of 250 patients will be
      enrolled from 3 VAMC sites and followed for 13 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>13 months</time_frame>
    <description>hemoglobin A1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From the Baseline in the Hr-QOL as Assessed by SF-36V at 13 Months of Study Enrollment</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-care Costs to the VHA</measure>
    <time_frame>13 months (during study) and 13 months (after the study) = 26 months</time_frame>
    <description>Institutional costs from health service utilization on the study patients during and 13 months after the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Pharmacist-led Group Visits</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacist-led group medical visits which consists of medication titration and behavioral modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients continued on usual care without pharmacist-led group medical visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Algorithm driven medication titration</intervention_name>
    <description>Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes</description>
    <arm_group_label>Pharmacist-led Group Visits</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Monitoring</intervention_name>
    <description>Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals</description>
    <arm_group_label>Pharmacist-led Group Visits</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group support</intervention_name>
    <description>Peer support are provided in the group setting</description>
    <arm_group_label>Pharmacist-led Group Visits</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Self efficacy</intervention_name>
    <description>Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision</description>
    <arm_group_label>Pharmacist-led Group Visits</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diabetic veterans with HbA1c &gt;7.0% and at least one of the following:

          -  being a smoker (any cigarette smoking &lt; 30 days)

          -  having an LDL &gt;100 mg/dl or a blood pressure &gt;130/80 mm Hg documented in at least two
             occasions within the last 6 months

          -  able to participate and discuss their DM and cardiac risk control in a group setting
             and sign informed consent

        Exclusion Criteria:

          -  patients without eligible cardiac risk factors within the last 6 months

          -  those who are unable to attend the group sessions

          -  or disease conditions such as psychiatric instability (acutely suicidal, psychotic) or
             organic brain injury that preclude them from performing DM self-care

          -  patients with conditions that would preclude them from standard algorithm-based
             medication dose titrations such as those who are pregnant or with complex
             co-morbidities as defined by New York Heart Association Class 3 or 4 heart failure,
             liver cirrhosis, end-stage renal disease on dialysis and end-stage cancer will be
             excluded from the study

          -  all women of childbearing age will have a pregnancy test before study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Chih Hank Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence VA Medical Center, Providence, RI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Health Care System (West Haven)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pacific Islands Health Care System, Honolulu</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819-1522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence VA Medical Center, Providence, RI</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taveira TH, Pirraglia PA, Cohen LB, Wu WC. Efficacy of a pharmacist-led cardiovascular risk reduction clinic for diabetic patients with and without mental health conditions. Prev Cardiol. 2008 Fall;11(4):195-200. doi: 10.1111/j.1751-7141.2008.00008.x.</citation>
    <PMID>19476571</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2007</study_first_posted>
  <results_first_submitted>December 4, 2014</results_first_submitted>
  <results_first_submitted_qc>December 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2014</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Clinical pharmacists</keyword>
  <keyword>guideline adherence</keyword>
  <keyword>group medical visits</keyword>
  <keyword>behavioral modification</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pharmacist-led Group Medical Visits</title>
          <description>Pharmacist-led group medical visits which consists of medication titration and behavioral modification
Algorithm driven medication titration: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
Monitoring: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
Group support: Peer support are provided in the group setting
Self efficacy: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Patients continued on usual care without pharmacist-led group medical visits</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pharmacist-led Group Medical Visits</title>
          <description>Pharmacist-led group medical visits which consists of medication titration and behavioral modification
Algorithm driven medication titration: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
Monitoring: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
Group support: Peer support are provided in the group setting
Self efficacy: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Patients continued on usual care without pharmacist-led group medical visits</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="8.7"/>
                    <measurement group_id="B2" value="65.0" spread="9.8"/>
                    <measurement group_id="B3" value="65.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent Hemoglobin A1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.5"/>
                    <measurement group_id="B2" value="8.2" spread="1.3"/>
                    <measurement group_id="B3" value="8.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.5" spread="19.0"/>
                    <measurement group_id="B2" value="136.2" spread="17.4"/>
                    <measurement group_id="B3" value="136.3" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.6" spread="29.8"/>
                    <measurement group_id="B2" value="93.7" spread="33.7"/>
                    <measurement group_id="B3" value="91.0" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist-led Group Medical Visits</title>
            <description>Pharmacist-led group medical visits which consists of medication titration and behavioral modification
Algorithm driven medication titration: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
Monitoring: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
Group support: Peer support are provided in the group setting
Self efficacy: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Patients continued on usual care without pharmacist-led group medical visits</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent Hemoglobin A1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="1.2"/>
                    <measurement group_id="O2" value="8.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From the Baseline in the Hr-QOL as Assessed by SF-36V at 13 Months of Study Enrollment</title>
        <time_frame>13 months</time_frame>
        <posting_date>04/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-care Costs to the VHA</title>
        <description>Institutional costs from health service utilization on the study patients during and 13 months after the intervention</description>
        <time_frame>13 months (during study) and 13 months (after the study) = 26 months</time_frame>
        <posting_date>04/2015</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c</title>
        <description>hemoglobin A1c</description>
        <time_frame>13 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist-led Group Medical Visits</title>
            <description>Pharmacist-led group medical visits which consists of medication titration and behavioral modification
Algorithm driven medication titration: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
Monitoring: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
Group support: Peer support are provided in the group setting
Self efficacy: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Patients continued on usual care without pharmacist-led group medical visits</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c</title>
          <description>hemoglobin A1c</description>
          <units>percent Hemoglobin A1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="1.3"/>
                    <measurement group_id="O2" value="8.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pharmacist-led Group Medical Visits</title>
          <description>Pharmacist-led group medical visits which consists of medication titration and behavioral modification
Algorithm driven medication titration: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
Monitoring: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
Group support: Peer support are provided in the group setting
Self efficacy: Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Patients continued on usual care without pharmacist-led group medical visits</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ER visits</sub_title>
                <description>Emergency room visits</description>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="117"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>Any cause hospitalization</description>
                <counts group_id="E1" events="40" subjects_affected="26" subjects_at_risk="117"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Any cause mortality</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia,</sub_title>
                <description>Required unscheduled visits to the provider</description>
                <counts group_id="E1" events="117" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" events="133" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Required unscheduled visits to the provider</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wen-Chih Wu, MD</name_or_title>
      <organization>Providence VA Medical Center</organization>
      <phone>4012737100 ext 6237</phone>
      <email>wen-chih.wu@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

